MONTREAL | preliminary results to allow the study on the colchicine to be continued in order to judge its effectiveness against the COVID-19.
“The clinical study COLCORONA will continue to recruit patients adult outpatients with COVID-19”, indicated on Friday the Montreal heart Institute (MHI) in a press release.
The institution follows the recommendation of the independent Committee of data monitoring.
“We are pleased to have reached this important milestone and look forward to the final results of the study COLCORONA to determine if the colchicine may prevent the complications in patients non-hospitalized patients with the COVID-19”, said Dr. Jean-Claude Tardif, director of the research center of the ICM and principal investigator of the study.
The study aims to determine whether colchicine can prevent the phenomenon of “storm major inflammatory” of the lungs, observed in adults with severe complications related to the COVID-19, a-t was specified.
COLCORONA coordinated by the coordination Centre for clinical trials, Montreal is funded in part by the government of Quebec.